Trial Profile
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Siponimod (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms EXPAND
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Mar 2024 The study has been Discontinued in Italy According to European Clinical Trials Database record.
- 24 Feb 2024 The study has been Discontinued in Portugal, According to European Clinical Trials Database record.
- 13 Oct 2023 Status changed from active, no longer recruiting to completed.